A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study

BACKGROUND: Platinum-based combinations are the standard second-line treatment for platinum-sensitive ovarian cancer (OC). This randomized phase II study was undertaken in order to compare the combination of carboplatin and pegylated liposomal doxorubicin (LD) with carboplatin and paclitaxel (CP) in...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Bafaloukos, Dimitrios, Linardou, Helena, Aravantinos, Gerasimos, Papadimitriou, Christos, Bamias, Aristotelis, Fountzilas, George, Kalofonos, Haralabos P, Kosmidis, Paris, Timotheadou, Eleni, Makatsoris, Thomas, Samantas, Epaminondas, Briasoulis, Evangelos, Christodoulou, Christos, Papakostas, Pavlos, Pectasides, Dimitrios, Dimopoulos, Athanasios M
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2010
Sujets:
Research article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2823653/
https://ncbi.nlm.nih.gov/pubmed/20055981
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1741-7015-8-3
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires